Evidence map›Paper›PMID 25375128›Full record

ArticlePLoS pathogens2014

Co-dependence of HTLV-1 p12 and p8 functions in virus persistence.

Cynthia A Pise-Masison, Maria Fernanda de Castro-Amarante, Yoshimi Enose-Akahata, R Cody Buchmann, Claudio Fenizia, Robyn Washington Parks, Dustin Edwards, Martina Fiocchi, Luiz Carlos Alcantara, Izabela Bialuk and 8 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Complete Rescue of HTLV-1Pathogens (Basel, Switzerland) · 2024
    Article
  11. Intercellular Transport of Viral Proteins.Results and problems in cell differentiation · 2024
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 5 countries.

Cynthia A Pise-MasisonAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America.
Maria Fernanda de Castro-AmaranteAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America.
Yoshimi Enose-AkahataViral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, United States of America.
R Cody BuchmannAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America.
Claudio FeniziaAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America.
Robyn Washington ParksAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America.
Dustin EdwardsAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America.
Martina FiocchiAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America.
Luiz Carlos AlcantaraOswaldo Cruz Foundation Salvador, Bahia, Brazil.
Izabela BialukDepartment of General and Experimental Pathology, Medical University in Białystok, Białystok, Poland.
Jhanelle GrahamViral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, United States of America.
Jean-Claude WalserEvolutionary Biology, Genetic Diversity Centre, University of Basel, Basel, Switzerland.
Katherine McKinnonVaccine Branch Flow Cytometry Core Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
Bernardo Galvão-CastroOswaldo Cruz Foundation Salvador, Bahia, Brazil.
Antoine GessainUnité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, Batiment Lwoff, Institut Pasteur, Paris, France.
David VenzonBiostatistics and Data Management Section, National Cancer Institute, Bethesda, Maryland, United States of America.
Steven JacobsonViral Immunology Section, Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, Bethesda, Maryland, United States of America.
Genoveffa FranchiniAnimal Models and Retroviral Vaccines Section, National Cancer Institute, Bethesda, Maryland, United States of America.
National Cancer Institute · USNational Institute of Neurological Disorders and Stroke · USFundação Oswaldo Cruz · BRInstitut Pasteur · FRMedical University of Białystok · PLUniversity of Basel · CH

Funding

Involvement Of Human Viruses Associated With Chronic Neurologic DiseaseZIANS002817 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI JACOBSON, STEVEN · 2009 to 2025
$26.5M
CCR VB FACS COREZICBC010936 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MCKINNON, KATHERINE · 2009 to 2025
$10.9M
Translational studies of human viruses and chronic neurologic diseaseZIANS003040 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI JACOBSON, STEVEN · 2009 to 2025
$10.1M
6 · The paper itself

Abstract

HTLV-1 orf-I is linked to immune evasion, viral replication and persistence. Examining the orf-I sequence of 160 HTLV-1-infected individuals; we found polymorphism of orf-I that alters the relative amounts of p12 and its cleavage product p8. Three groups were identified on the basis of p12 and p8 expression: predominantly p12, predominantly p8 and balanced expression of p12 and p8. We found a significant association between balanced expression of p12 and p8 with high viral DNA loads, a correlate of disease development. To determine the individual roles of p12 and p8 in viral persistence, we constructed infectious molecular clones expressing p12 and p8 (D26), predominantly p12 (G29S) or predominantly p8 (N26). As we previously showed, cells expressing N26 had a higher level of virus transmission in vitro. However, when inoculated into Rhesus macaques, cells producing N26 virus caused only a partial seroconversion in 3 of 4 animals and only 1 of those animals was HTLV-1 DNA positive by PCR. None of the animals exposed to G29S virus seroconverted or had detectable viral DNA. In contrast, 3 of 4 animals exposed to D26 virus seroconverted and were HTLV-1 positive by PCR. In vitro studies in THP-1 cells suggested that expression of p8 was sufficient for productive infection of monocytes. Since orf-I plays a role in T-cell activation and recognition; we compared the CTL response elicited by CD4+ T-cells infected with the different HTLV-1 clones. Although supernatant p19 levels and viral DNA loads for all four infected lines were similar, a significant difference in Tax-specific HLA.A2-restricted killing was observed. Cells infected with Orf-I-knockout virus (12KO), G29S or N26 were killed by CTLs, whereas cells infected with D26 virus were resistant to CTL killing. These results indicate that efficient viral persistence and spread require the combined functions of p12 and p8.

Indexed as

AnimalsCD4-Positive T-LymphocytesDNA, ViralFemaleGene Expression Regulation, ViralGene Knockdown TechniquesHTLV-I InfectionsHumansHuman T-lymphotropic virus 1Macaca mulattaMaleViral Regulatory and Accessory ProteinsDNA, Viralp12I protein, Human T-lymphotropic virus 1Viral Regulatory and Accessory Proteins

Identifiers

PMID25375128
PMCPMC4223054
OpenAlexW2079611331

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.